Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 20/20 | 1.00 |
| ▸ | AURKB | Q96GD4 | 13/20 | 1.00 |
| ▸ | SYK | P43405 | 3/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4056160 | 0.91 | AURKA (1.00) | AURKAAURKBSYK | |
| SCHEMBL4061131 | 0.89 | AURKA (1.00) | AURKAAURKBSYK | |
| SCHEMBL4057531 | 0.83 | AURKA (1.00) | AURKAAURKBSYK | |
| SCHEMBL4060163 | 0.82 | AURKA (0.81) | AURKAAURKBSYK | |
| SCHEMBL4057597 | 0.81 | AURKA (1.00) | AURKAAURKBSYK | |
| SCHEMBL4058482 | 0.81 | AURKA (0.74) | AURKAAURKBSYK | |
| SCHEMBL4057805 | 0.79 | AURKA (1.00) | AURKAAURKBSYK | |
| SCHEMBL4065737 | 0.77 | AURKA (0.80) | AURKAAURKBSYK | |
| SCHEMBL4057126 | 0.76 | AURKA (0.82) | AURKAAURKBSYK | |
| SCHEMBL4059036 | 0.74 | AURKA (1.00) | AURKAAURKBSYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016130460-A9 | PHTHALAZINONE PYRAZOLE DERIVATIVES FOR TREATING RETINAL DEGENERATIVE DISEASE | THE JOHNS HOPKINS UNIVERSITY (US) | 2016-09-15 | — | — | WO | claimed |
| WO-2016130460-A2 | PHTHALAZINONE PYRAZOLE DERIVATIVES FOR TREATING RETINAL DEGENERATIVE DISEASE | THE JOHNS HOPKINS UNIVERSITY (US) | 2016-08-18 | — | — | WO | claimed |
| EP-1794148-B1 | NOVEL PHTHALAZINONE DERIVATIVES, AS AURORA-A KINASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2009-04-15 | — | — | EP | claimed |
| US-7226923-B2 | Phthalazinone derivatives | HOFFMAN-LA ROCHE INC. (US) | 2007-06-05 | — | — | US | claimed |
| US-20060089359-A1 | Phthalazinone derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2006-04-27 | — | — | US | claimed |
| WO-2016130460-A2 | PHTHALAZINONE PYRAZOLE DERIVATIVES FOR TREATING RETINAL DEGENERATIVE DISEASE | THE JOHNS HOPKINS UNIVERSITY (US) | 2016-08-18 | — | — | WO | disclosed |
| EP-1268421-B1 | PHENYL-SUBSTITUTED INDOLES AS HISTAMINE H3-RECEPTOR ANTAGONISTS | ORTHO MCNEIL PHARM INC (US) | 2009-05-06 | — | — | EP | disclosed |
| EP-1794148-B1 | NOVEL PHTHALAZINONE DERIVATIVES, AS AURORA-A KINASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2009-04-15 | — | — | EP | disclosed |
| EP-1794148-A1 | NOVEL PHTHALAZINONE DERIVATIVES, AS AURORA-A KINASE INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2007-06-13 | — | — | EP | disclosed |
| US-7226923-B2 | Phthalazinone derivatives | HOFFMAN-LA ROCHE INC. (US) | 2007-06-05 | — | — | US | disclosed |
| US-20060089359-A1 | Phthalazinone derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2006-04-27 | — | — | US | disclosed |
| WO-2006032518-A1 | NOVEL PHTHALAZINONE DERIVATIVES, AS AURORA-A KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-03-30 | — | — | WO | disclosed |
| US-6872834-B2 | Phenyl-substituted indoles and indazoles | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2005-03-29 | — | — | US | disclosed |
| EP-1268421-A2 | PHENYL-SUBSTITUTED INDOLES AS HISTAMINE H3-RECEPTOR ANTAGONISTS | Ortho-McNeil Pharmaceutical, Inc. (US) | 2003-01-02 | — | — | EP | disclosed |
| US-20020006928-A1 | Phenyl-substituted indoles and indazoles | ORTHO MCNEIL PHARMACEUTICAL, INC. | 2002-01-17 | — | — | US | disclosed |
| WO-2001074773-A2 | PHENYL-SUBSTITUTED INDOLES AS HISTAMINE H3-RECEPTOR ANTAGONISTS | ORTHO MCNEIL PHARMACEUTICAL, INC. (US) | 2001-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060089359-A1 | Phthalazinone derivatives | SDHA, SDHB, CYP3A5 | AURKA 1585/4885AURKB 1484/4885SYK 3513/4885 |
| US-20020006928-A1 | Phenyl-substituted indoles and indazoles | IDO1, IDO2, AADAC | AURKA 174/4885AURKB 147/4885SYK 2203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.